Molecular phenotype of breast cancer according to time since last pregnancy in a large cohort of young women

Oncologist

Volumn 20, Issue 7, 2015, Pages 713-718

  Collins, Laura C ^a,e   Gelber, Shari ^b   Marotti, Jonathan D ^c   White, Sarah ^d   Ruddy, Kathryn ^f   Brachtel, Elena F ^e,g   Schapira, Lidia ^e,g   Come, Steven E ^a,e   Borges, Virginia F ^h   Schedin, Pepper ⁱ   Warner, Ellen ^j   Wensley, Taylor ^b   Tamimi, Rulla M ^e,k,l   Winer, Eric P ^b,e   Partridge, Ann H ^b,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MAYO CLINIC   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF COLORADO CANCER CENTER   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Breast cancer; Molecular phenotypes; Pregnancy associated breast cancer; Young women

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; QUESTIONNAIRE; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CLINICAL TRIAL; COHORT ANALYSIS; METABOLISM; MULTICENTER STUDY; PARITY; PATHOLOGY; REPRODUCTIVE HISTORY; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; PARITY; PREGNANCY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCTIVE HISTORY; YOUNG ADULT;

EID: 84936885952     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0412     Document Type: Article

References (47)

1. Albrektsen G, Heuch I, Hansen S et al. Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. Br J Cancer 2005;92:167–175.
2. Bruzzi P, Negri E, La Vecchia C et al. Short term increase in risk of breast cancer after full term pregnancy. BMJ 1988;297:1096–1098.
3. Lambe M, Hsieh C, Trichopoulos D et al. Transient increase in the risk of breast cancer after giving birth. N Engl JMed 1994;331:5–9.
4. Fisher ER, Anderson S, Tan-Chiu E et al. Fifteenyear prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer 2001;91(suppl): 1679–1687.
5. Gajdos C, Tartter PI, Bleiweiss IJ et al. Stage 0 to stage III breast cancer in young women. J Am Coll Surg 2000;190:523–529.
6. Han W, Kim SW, Park IA et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 2004;4:82.
7. Kroman N, Jensen MB, Wohlfahrt J et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000;320: 474–478.
8. Rapiti E, Fioretta G, Verkooijen HM et al. Survival of young and older breast cancer patients in Geneva from1990 to 2001. Eur J Cancer 2005;41: 1446–1452.
9. Adami HO, Malker B, Holmberg L et al. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986;315:559–563.
10. Bonnier P, Romain S, Dilhuydy JM et al. Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 1997;72:720–727.
11. Olson SH, Zauber AG, Tang J et al. Relation of time since last birth and parity to survival of young women with breast cancer. Epidemiology 1998;9: 669–671.
12. Johansson AL, Andersson TM, Hsieh CC et al. Stage at diagnosis and mortality in women with pregnancy-associated breast cancer (PABC). Breast Cancer Res Treat 2013;139:183–192.
13. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406:747–752.
14. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869–10874.
15. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418–8423.
16. Brenton JD, Carey LA, Ahmed AA et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350–7360.
17. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492–2502.
18. Carvalho FM, Bacchi LM, Santos PP et al. Triplenegative breast carcinomas are a heterogeneous entity that differs between young and old patients. Clinics (Sao Paulo) 2010;65:1033–1036.
19. Alvarado-Cabrero IV-CR, Barroso-Bravo S. Breast cancer in Mexican women younger than age 45 years. A clinicopathologic study of 1,320 cases. Mod Pathol 2011;24(suppl 1s):26A.
20. Collins LC, Marotti JD, Gelber S et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 2012;131:1061–1066.
21. Pilewskie M, Gorodinsky P, Fought A et al. Association between recency of last pregnancy and biologic subtype of breast cancer. Ann Surg Oncol 2012;19:1167–1173.
22. Callihan EB, Gao D, Jindal S et al. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancyassociated breast cancer. Breast Cancer Res Treat 2013;138:549–559.
23. Nagatsuma AK, Shimizu C, Takahashi F et al. Impact of recent parity on histopathological tumor features and breast cancer outcome in premenopausal Japanese women. Breast Cancer Res Treat 2013;138:941–950.
24. Peri S, de Cicco RL, Santucci-Pereira J et al. Defining the genomic signature of the parous breast. BMCMed Genomics 2012;5:46.
25. Russo J, Balogh GA, Russo IH. Full-term pregnancy induces a specific genomic signature in the human breast. Cancer Epidemiol Biomarkers Prev 2008;17:51–66.
26. Asztalos S, Gann PH, Hayes MK et al. Gene expression patterns in the human breast after pregnancy. Cancer Prev Res (Phila) 2010;3:301–311.
27. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368–1376.
28. Cheang MCU, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736–750.
29. Tamimi RM, Baer HJ, Marotti J et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008;10:R67.
30. Yang XR, Sherman ME, Rimm DL et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007;16:439–443.
31. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367–5374.
32. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes—dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736–1747.
33. Keegan TH, Press DJ, Tao L et al. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res 2013;15:R95.
34. Partridge AHHM, Hughes ME, Ottesen RA et al. The effect of age on delay in diagnosis and stage of breast cancer. The Oncologist 2012;17:775–782.
35. Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia 2009;14:87–98.
36. Rosner B, Colditz GA. Nurses’ health study: logincidence mathematical model of breast cancer incidence. J Natl Cancer Inst 1996;88:359–364.
37. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 2006;6:281–291.
38. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784–2795.
39. Lyons TR, O’Brien J, Borges VF et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 2011;17:1109–1115.
40. Colditz GA, Rosner BA, Chen WY et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218–228.
41. Anders CK, Hsu DS, Broadwater G et al. Young ageat diagnosis correlates withworseprognosisand defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008;26: 3324–3330.
42. Ahn SH, Son BH, KimSWet al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: Nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 2007;25: 2360–2368.
43. Colleoni M, Rotmensz N, Robertson C et al. Very young women (,35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002;13:273–279.
44. Keegan TH, DeRouen MC, Press DJ et al. Occurrence of breast cancer subtypes in adolescent andyoungadultwomen. BreastCancer Res 2012;14: R55.
45. O’Brien KM, Cole SR, Tse CK et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010;16:6100–6110.
46. Caldarella A, Crocetti E, Bianchi S et al. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res 2011;17:753–758.
47. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19: 264–271.